TY - JOUR
T1 - Examining racial differences in diffuse large B-cell lymphoma presentation and survival
AU - Flowers, Christopher R.
AU - Shenoy, Pareen J.
AU - Borate, Uma
AU - Bumpers, Kevin
AU - Douglas-Holland, Tanyanika
AU - King, Nassoma
AU - Brawley, Otis W.
AU - Lipscomb, Joseph
AU - Lechowicz, Mary Jo
AU - Sinha, Rajni
AU - Grover, Rajinder S.
AU - Bernal-Mizrachi, Leon
AU - Kowalski, Jeanne
AU - Donnellan, Will
AU - The, Angelina
AU - Reddy, Vishnu
AU - Jaye, David L.
AU - Foran, James
N1 - Funding Information:
Research reported in this publication was also supported by the National Cancer Institute of the National Institutes of Health under Dr. Flowers’ Award Number R21CA158686. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors appreciate the support of Alison Maggioncalda, Miray Seward, Gia Garrett, Neha Malik and Dionne Duc in the process of data collection.
Funding Information:
This work was supported by Dr. Flowers’ Georgia Cancer Coalition Distinguished Scientist Award and American Society of Hematology Amos Medical Faculty Development Award, and Dr. Foran ’s University of Alabama at Birmingham Health Services Foundation Scholar of Excellence Award.
PY - 2013/2
Y1 - 2013/2
N2 - We performed a retrospective cohort analysis of 701 (533 white and 144 black) patients with diffuse large B-cell lymphoma (DLBCL) treated at two referral centers in southern United States between 1981 and 2010. Median age of diagnosis for blacks was 50 years vs. 57 years for whites (p < 0.001). A greater percentage of blacks presented with elevated lactate dehydrogenase levels, B-symptoms and performance status ≥ 2. More whites (8%) than blacks (3%) had a positive family history of lymphoma (p = 0.048). There were no racial differences in the use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 52% black vs. 47% white, p = 0.73). While black race predicted worse survival among patients treated with CHOP (hazard ratio [HR] 1.8, p < 0.001), treatment with R-CHOP was associated with improved survival irrespective of race (HR 0.61, p = 0.01). Future studies should examine biological differences that may underlie the observed racial differences in presentation and outcome.
AB - We performed a retrospective cohort analysis of 701 (533 white and 144 black) patients with diffuse large B-cell lymphoma (DLBCL) treated at two referral centers in southern United States between 1981 and 2010. Median age of diagnosis for blacks was 50 years vs. 57 years for whites (p < 0.001). A greater percentage of blacks presented with elevated lactate dehydrogenase levels, B-symptoms and performance status ≥ 2. More whites (8%) than blacks (3%) had a positive family history of lymphoma (p = 0.048). There were no racial differences in the use of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; 52% black vs. 47% white, p = 0.73). While black race predicted worse survival among patients treated with CHOP (hazard ratio [HR] 1.8, p < 0.001), treatment with R-CHOP was associated with improved survival irrespective of race (HR 0.61, p = 0.01). Future studies should examine biological differences that may underlie the observed racial differences in presentation and outcome.
KW - CHOP regimen
KW - Diffuse large B-cell lymphoma
KW - Disparities
KW - Outcomes
KW - R-CHOP regimen
KW - Race
UR - http://www.scopus.com/inward/record.url?scp=84872011523&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872011523&partnerID=8YFLogxK
U2 - 10.3109/10428194.2012.708751
DO - 10.3109/10428194.2012.708751
M3 - Article
C2 - 22800091
AN - SCOPUS:84872011523
SN - 1042-8194
VL - 54
SP - 268
EP - 276
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 2
ER -